Cell line · CVCL_8054
Papers38
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 38
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ImmTACs overcome cytotoxic T cell suppression. | Immunother Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineering editopes through programmable RNA editing toward tumor neoantigen generation. | EMBO J | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhancement of Ferroptosis in Escape Variant Tumor Cells by IFNγ Derived from Antigen-Specific T Cells Controls Tumor with Heterogeneity. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MITF maintains genome stability in nonmelanocyte lineages. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enhanced IFNy response in dedifferentiated melanoma cells is due to chromatin remodeling as revealed by ATAC-seq. | Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD-L1 in melanoma. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nutrient Availability Dictates Cancer Metabolism-Based Therapeutic Responses to Nononcology Drugs. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes). | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Galectin-9 regulates dendritic cell polarity and uropod contraction by modulating RhoA activity. | J Cell Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IgSF11-RAP1 signaling promotes cell migration and invasion of cutaneous melanoma. | Cell Commun Signal | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor cell spheroid-induced suppression of primary human cytotoxic T cells as a scalable in vitro model of exhaustion. | Immunother Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Human CSPG4-targeting CAR-macrophages inhibit melanoma growth. | Oncogene | 2025 | Its Methods give the RRID and name the line | PubMed | |
| NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. | Cancer Immunol Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of CSF-1R and IL-6R prevents conversion of cDC2s into immune incompetent tumor-induced DC3s boosting DC-driven therapy potential. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. | J Transl Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. | Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. | Front Immunol | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8054/papers